Mostrar el registro sencillo del ítem

Artículo

dc.creatorMingorance Gutiérrez, María del Carmenes
dc.creatorGonzález del Pozo, Maríaes
dc.creatorHerrera González, María Doloreses
dc.creatorÁlvarez de Sotomayor Paz, Maríaes
dc.date.accessioned2020-05-14T14:35:17Z
dc.date.available2020-05-14T14:35:17Z
dc.date.issued2009
dc.identifier.citationMingorance Gutiérrez, M.d.C., González del Pozo, M., Herrera González, M.D. y Álvarez de Sotomayor Paz, M. (2009). Oral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker rats. British Journal of Nutrition, 102 (8), 1145-1153.
dc.identifier.issn0007-1145es
dc.identifier.issn1475-2662es
dc.identifier.urihttps://hdl.handle.net/11441/96704
dc.description.abstractPropionyl-l-carnitine (PLC) is an SCFA esterified to carnitine that plays an important role in fatty acid oxidation and energy expenditure, in addition to having a protective effect on the endothelium. In order to evaluate the effect of PLC on an animal model of obesity, insulin resistance and, consequently, endothelial dysfunction, lean and obese Zucker rats (OZR) received either vehicle- or PLC-supplemented drinking water (200mg/kg per d) for 20 weeks. Body weight, food intake, systolic blood pressure and heart rate were controlled weekly and an oral glucose tolerance test was performed. Fasting glucose, TAG, cholesterol, HDL, NEFA, adiponectin and insulin were analysed in serum. Visceral adipose tissue and liver were weighed and liver TAG liver composition was evaluated. Endothelial and vascular functions were assessed in the aorta and small mesenteric arteries by response to acetylcholine, sodium nitroprusside and phenylephrine (Phe); NO participation was evaluated after incubation with the NO synthase (NOS) inhibitor NG-nitro-l-arginine methyl ester (l-NAME) and endothelial NOS protein expression by Western blotting. PLC decreased body-weight gain, food intake, adiposity, insulin serum concentration and TAG liver content and improved insulin resistance. Aortae from OZR receiving either vehicle or PLC exhibited a lower contractile response to Phe. PLC-treated OZR showed an enhanced release of endothelial NO upon the adrenergic stimulation. The protection of vascular function found after treatment with PLC in an animal model of insulin resistance supports the necessity of clinical trials showing the effect of l-carnitine supplements on metabolic disorders.es
dc.description.sponsorshipJunta de Andalucía CTS-178es
dc.formatapplication/pdfes
dc.format.extent9 p.es
dc.language.isoenges
dc.publisherCambridge University Presses
dc.relation.ispartofBritish Journal of Nutrition, 102 (8), 1145-1153.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectInsulin resistancees
dc.subjectMetabolic syndromees
dc.subjectObese Zucker ratses
dc.subjectPropionyl-l-carnitinees
dc.titleOral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker ratses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Farmacologíaes
dc.relation.projectIDCTS-178es
dc.relation.publisherversionhttp://dx.doi.org/10.1017/S0007114509389230es
dc.identifier.doi10.1017/S0007114509389230es
dc.journaltitleBritish Journal of Nutritiones
dc.publication.volumen102es
dc.publication.issue8es
dc.publication.initialPage1145es
dc.publication.endPage1153es

FicherosTamañoFormatoVerDescripción
Oral supplementation of propio ...322.1KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional